View

The Study

Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

In simple terms

This study tested two drugs on cancer cells in a dish and in mice, and saw that the cancer grew slower when both drugs were used together. But it didn’t test this on real people, so we can’t say it will work in humans yet—it’s just a very early hint that it might help.

18%

Analysis score

18/ 90

Maximum 90 for a randomized controlled trial.

Where the score came from

Reporting35
Methodology57
Publication100
Statistical54
Study type (basis of the score)
Randomized Controlled Trial
Level 1b - Individual RCT
What’s the bottom line?

Some pancreatic cancers have two broken genes: MTAP and KRAS. One drug (BMS-986504) targets the MTAP-broken weakness, and another drug blocks the KRAS cancer driver. When used together, they work much better than either alone.

Where does this study sit?

Reviews of RCTs (Meta-analyses)

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Randomized Trials
Level 1b
18

18 / 100

Quality score

Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.

Cannot establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

  1. 1Yes — this combo could help a large group of pancreatic cancer patients (22% have MTAP deletion and KRAS mutations) who currently have few effective treatments.
  2. 2In mice with this cancer type, the combo shrank tumors and kept them shrunk for nearly twice as long as the KRAS drug alone.
  3. 3The PRMT5 drug also messed up how cancer cells read their genes, especially for vital proteins.

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data

Publication

Journal

Cancer research

Year

2025

Authors

Kristina Drizyte-Miller, Lars D. Engstrom, Jeffrey A. Klomp, Clint A. Stalnecker, Addison G Stamey, Khalilah E Taylor, Mallory K Roach, Ryan Robb, Laurie Waters, Andrew Calinisan, Seamus E. Degan, Wen-Hsuan Chang, Xousaen M Helu, David Nguyen, E. Baldelli, M. Pierobon, Emanuel F. Petricoin, David M Briere, Jill Hallin, James G Christensen, Kirsten L. Bryant, Adrienne D. Cox, Peter Olson, C. Der

Open Access
7 citations
Analysis v5
Fit Body Science verdict — we translate health studies into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.